11 results on '"Villanueva, Vicente"'
Search Results
2. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
- Author
-
Lawthom, Charlotte, Peltola, Jukka, McMurray, Rob, Dodd, Emma, and Villanueva, Vicente
- Published
- 2018
- Full Text
- View/download PDF
3. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures
- Author
-
Villanueva, Vicente, Holtkamp, Martin, Delanty, Norman, Rodriguez-Uranga, Juan, McMurray, Rob, and Santagueda, Patricia
- Published
- 2017
- Full Text
- View/download PDF
4. Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli.
- Author
-
Sales, Francisco, Chaves, João, McMurray, Rob, Loureiro, Rui, Fernandes, Hélder, and Villanueva, Vicente
- Subjects
LENNOX-Gastaut syndrome ,EPILEPSY ,SEIZURES (Medicine) ,ACETATES ,ANTICONVULSANTS ,EVIDENCE - Abstract
Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients included in the Euro‐Esli study who had focal seizures associated with post‐stroke epilepsy (PSE). Materials and Methods: Euro‐Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment and at final follow‐up ["last visit"]) included rates of response (≥50% seizure frequency reduction), seizure freedom (no seizures since at least the prior visit) and retention. Safety/tolerability was assessed throughout ESL treatment by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc analysis was conducted of patients with PSE versus patients without PSE ("non‐PSE"). Results: Of 1656 patients included in the analysis, 76 (4.6%) had PSE and 1580 (95.4%) had non‐PSE. Compared with non‐PSE patients, PSE patients were significantly older, had significantly shorter epilepsy duration, significantly lower total baseline seizure frequency, and were treated with significantly fewer prior and concomitant antiepileptic drugs (P <.001 for all). At the last visit, the responder rate was significantly higher in PSE versus non‐PSE patients (72.9% vs 60.6%; P =.040), as was the seizure freedom rate (48.6% vs 31.7%; P =.003). After 12 months, retention was significantly higher in PSE versus non‐PSE patients (87.8% vs 77.4%; P =.035). The incidence of AEs was similar for PSE versus non‐PSE patients (36.0% vs 35.8%; P =.966). Conclusions: These findings suggest that ESL may be an effective and well‐tolerated treatment option for patients with focal seizures due to PSE. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. THUR 058 Eslicarbazepine acetate as monotherapy in clinical practice
- Author
-
McMurray Rob, Delanty Norman, and Villanueva Vicente
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Responder rate ,Clinical Practice ,Psychiatry and Mental health ,Pooled analysis ,Tolerability ,Eslicarbazepine acetate ,Internal medicine ,medicine ,Surgery ,In patient ,Neurology (clinical) ,Adverse effect ,business ,medicine.drug - Abstract
PurposeTo assess eslicarbazepine acetate (ESL) as monotherapy in everyday clinical practice.MethodEuro-Esli was a pooled analysis of 14 European studies. In a subanalysis, data were compared for patients treated initially with ESL monotherapy versus adjunctive therapy, and for patients treated at last visit with ESL monotherapy versus adjunctive therapy.Assessments included responder rate (≥50% seizure frequency reduction), seizure freedom rate (seizure freedom at least since prior visit) and incidence of adverse events (AEs).ResultsESL was used as monotherapy in 88/2045 and 229/1340 patients initially and at last visit, respectively. At 12 months, responder and seizure freedom rates were significantly higher in patients treated initially with ESL monotherapy versus adjunctive therapy (responder: 94.1% versus 74.8%; seizure freedom: 88.2% versus 39.0%), and in patients treated at last visit with ESL monotherapy versus adjunctive therapy (responder: 93.2% versus 70.4%; seizure freedom: 77.4% versus 25.9%). Overall incidence of AEs was similar in patients treated initially with ESL monotherapy and adjunctive therapy (29.4% versus 34.4%), and in patients treated at last visit with ESL monotherapy and adjunctive therapy (27.1% versus 30.8%).ConclusionESL was significantly more effective when used as monotherapy compared with adjunctive therapy; safety/tolerability was generally comparable.Supported by Eisai
- Published
- 2018
6. WED 063 Eslicarbazepine acetate switch from carbamazepine or oxcarbazepine
- Author
-
McMurray Rob, Peltola Jukka, and Villanueva Vicente
- Subjects
medicine.medical_specialty ,business.industry ,Carbamazepine ,Discontinuation ,Responder rate ,Psychiatry and Mental health ,Tolerability ,Eslicarbazepine acetate ,Internal medicine ,medicine ,Surgery ,In patient ,Neurology (clinical) ,Adverse effect ,Oxcarbazepine ,business ,medicine.drug - Abstract
PurposeTo investigate eslicarbazapine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine in clinical practice.MethodEuro-Esli was a pooled analysis of 14 European studies. Data were analysed for patients transitioning from carbamazepine and oxcarbazepine to ESL due to lack of efficacy or poor tolerability. Responder rate (≥50% seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months of ESL treatment, and at last visit. Safety/tolerability analysis evaluated adverse events (AEs) and ESL discontinuation due to AEs.ResultsEuro-Esli included 2058 patients; 233 (11.3%) transitioned from carbamazepine and 134 (6.5%) transitioned from oxcarbazepine. After 12 months, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n=163) were 70.0% and 30.9%, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n=90) were 57.1% and 25.0%, respectively. Among patients who transitioned from carbamazepine (n=64) and oxcarbazepine (n=61) due to poor tolerability, 26.6% and 39.5% experienced AEs; 8.3% and 6.8% discontinued ESL due to AEs, respectively.ConclusionESL may be a useful option for patients experiencing intolerable AEs or not achieving adequate control with carbamazepine or oxcarbazepine.Supported by Eisai.
- Published
- 2018
7. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
- Author
-
Rocamora, Rodrigo, Peltola, Jukka, Assenza, Giovanni, McMurray, Rob, and Villanueva, Vicente
- Abstract
Purpose: To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by analysing data from the Euro-Esli study.Methods: Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments included responder rate (≥50 % seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit), assessed after 3, 6 and 12 months of ESL treatment, and at the last visit. Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively. Data were analysed for cohorts of patients who transitioned from carbamazepine and oxcarbazepine to ESL either due to lack of efficacy or poor tolerability.Results: Euro-Esli included 2058 patients, of whom 233 (11.3 %) transitioned from carbamazepine to ESL and 134 (6.5 %) transitioned from oxcarbazepine to ESL. After 12 months of ESL treatment, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n = 163) were 70.0 % and 30.9 %, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n = 90) were 57.1 % and 25.0 %, respectively. Among patients who transitioned from carbamazepine and oxcarbazepine to ESL due to poor tolerability (n = 64 and n = 61, respectively), 26.6 % and 39.5 % experienced AEs, and 8.3 % and 6.8 % discontinued ESL due to AEs, respectively.Conclusion: ESL was efficacious and generally well tolerated in patients transitioning from carbamazepine or oxcarbazepine in clinical practice due to inadequate seizure control or intolerable AEs with these agents. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro‐Esli.
- Author
-
Holtkamp, Martin, Delanty, Norman, Sales, Francisco, Serratosa, Jose, McMurray, Rob, and Villanueva, Vicente
- Subjects
SPASM treatment ,SIDE effects of anticonvulsants ,TREATMENT effectiveness ,DRUG efficacy ,MEDICATION safety - Abstract
Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) monotherapy in clinical practice in Europe. Materials and methods: Euro‐Esli was a pooled analysis of 14 European clinical practice studies. Responder rate (≥50% seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months of ESL treatment and at last visit. Adverse events (AEs) and AEs leading to ESL discontinuation were assessed throughout follow‐up. A subanalysis was conducted to assess outcomes for patients treated initially with ESL monotherapy and for patients treated at the last visit with ESL monotherapy. Results: ESL was used as monotherapy in 88/2045 (4.3%) patients initially and in 229/1340 (17.1%) patients at the last visit. At 12 months, responder and seizure freedom rates were 94.1% and 88.2%, respectively, in patients treated initially with ESL monotherapy, and 93.2% and 77.4%, respectively, in patients treated at the last visit with ESL monotherapy. Corresponding values for patients treated initially with ESL adjunctive therapy were 74.8% and 39.0%, respectively; and for patients treated at the last visit with ESL adjunctive therapy, corresponding values were 70.4% and 25.9%, respectively. Safety and tolerability were generally comparable in patients treated with ESL as monotherapy or adjunctive therapy. The most commonly reported AEs (≥5% of patients in any group) were dizziness, somnolence, instability/ataxia, and fatigue. Conclusions: These clinical practice data support the use of ESL as monotherapy, as well as adjunctive therapy, for focal‐onset seizures, complementing evidence from clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
- Author
-
Elger, Christian, Koepp, Mathias, Trinka, Eugen, Villanueva, Vicente, Chaves, João, Ben‐Menachen, Elinor, Kowacs, Pedro A., Gil‐Nagel, António, Moreira, Joana, Gama, Helena, Rocha, José‐Francisco, and Soares‐da‐Silva, Patrício
- Subjects
AZEPINES ,DRUG efficacy ,MEDICATION safety ,SPASM treatment ,PLACEBOS ,RANDOMIZED controlled trials ,THERAPEUTICS - Abstract
Purpose Pooled evaluation of the key efficacy and safety profile of eslicarbazepine acetate ( ESL) added-on to stable antiepileptic therapy in adults with focal-onset seizures. Methods Data from 1703 patients enrolled in four phase III double-blind, randomized, placebo-controlled studies were pooled and analyzed. Following a 2 week titration period, ESL was administered at 400 mg, 800 mg, and 1200 mg once-daily doses for 12 weeks (maintenance period). Pooled efficacy variable was standardized (/4 weeks) seizure frequency ( SSF) analyzed over the maintenance period as reduction in absolute and relative SSF and proportion of responders (≥50% reduction in SSF). Pooled safety was analyzed by means of adverse events and clinical laboratory assessments. Results SSF was significantly reduced with ESL 800 mg ( P < 0.0001) and 1200 mg ( P < 0.0001) compared to placebo. Median relative reduction in SSF was 33.4% for ESL 800 mg and 37.8% for 1200 mg (placebo: 17.6%), and responder rate was 33.8% and 43.1% (placebo: 22.2%). ESL was more efficacious than placebo regardless of gender, geographical region, epilepsy duration, age at time of diagnosis, seizure type, and type of concomitant antiepileptic drugs ( AED). Incidence of adverse events ( AEs) and AEs leading to discontinuation was dose dependent. Most common AEs (>10% patients) were dizziness, somnolence, and nausea. The incidence of treatment-emergent AEs (dizziness, somnolence, ataxia, vomiting, and nausea) was lower in patients who began taking ESL 400 mg (followed by 400 mg increments to 800 or 1200 mg) than in those who began taking ESL 600 mg or 800 mg. Conclusions Once-daily ESL 800 mg and 1200 mg showed consistent results across all efficacy and safety endpoints, independent of study population characteristics and type of concomitant AEDs. Treatment initiated with ESL 400 mg followed by 400 mg increments to 800 or 1200 mg provides optimal balance of efficacy and tolerability. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study.
- Author
-
Doherty, Colin P., Rheims, Sylvain, Assenza, Giovanni, Boero, Giovanni, Chaves, João, McMurray, Rob, and Villanueva, Vicente
- Subjects
- *
PEOPLE with epilepsy , *INTELLECTUAL disabilities , *PSYCHOTHERAPY patients , *COMORBIDITY , *ACETATES , *INTELLECTUAL development - Abstract
Psychiatric and intellectual comorbidities are common in patients with epilepsy. However, data on the use of antiepileptic drugs in these patients are still lacking. This study assessed the real-world effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients with intellectual disability and psychiatric comorbidities, including a separate analysis specifically in those with depression, using data from the Euro-Esli study. Effectiveness measures included responder and seizure freedom rates. Safety and tolerability were assessed by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively. Of the 2058 patients initially included in the Euro-Esli study, 952 patients had intellectual disability data available, 1138 had psychiatric comorbidity data available and 1134 had depression data available. Of those who had intellectual or psychiatric comorbidity data available, 11.3% (108/952) suffered from intellectual disability, 24.9% (283/1138) had a psychiatric disorder, including depression, and 12.4% (141/1134) specifically had depression. Responder and seizure freedom rates were generally comparable between patients with psychiatric comorbidity and those without, and patients with depression and those without. However, responder and seizure freedom rates were significantly lower in patients with intellectual disability compared with those without. Overall, patients with psychiatric and intellectual comorbidities experienced more AEs and AEs leading to ESL discontinuation than patients without these comorbidities. The incidence of psychiatric AEs was not significantly different for patients with psychiatric comorbidities or depression than those without, and the incidence of cognitive AEs was not significantly different for patients with intellectual disability than those without. These findings suggest that ESL is effective in patients with psychiatric and intellectual comorbidities and that its use in these patients is unlikely to exacerbate existing psychiatric or cognitive disturbances. • Euro-Esli assessed the effectiveness of eslicarbazepine acetate in clinical practice. • Psychiatric and intellectual comorbidities are common in patients with epilepsy. • Eslicarbazepine acetate was effective in Euro-Esli patients with these comorbidities. • Adverse events were more common in patients with versus without these comorbidities. • However, existing psychiatric or cognitive conditions did not seem to be exacerbated. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate — Expert opinion.
- Author
-
Peltola, Jukka, Holtkamp, Martin, Rocamora, Rodrigo, Ryvlin, Philippe, Sieradzan, Kasia, and Villanueva, Vicente
- Subjects
- *
CARBAMAZEPINE , *ACETATES , *CYTOCHROME P-450 , *OLDER patients , *TREATMENT of epilepsy - Abstract
There is currently a lack of guidance on methodology and special considerations for transitioning patients from oxcarbazepine (OXC) or carbamazepine (CBZ) to eslicarbazepine acetate (ESL), if deemed clinically necessary. An advisory panel of epilepsy experts was convened to share their experience on the use of adjunctive ESL in clinical practice and to provide practical recommendations to help address this gap. When changing over from OXC to ESL, an OXC:ESL dose ratio of 1:1 should be employed to calculate the ESL target dose, and the changeover can take place overnight. No changes to comedication are required. Since CBZ has a different mechanism of action to ESL and is a stronger inducer of cytochrome P450 (CYP) enzymes, the transitioning of patients from CBZ to ESL requires careful consideration on a patient-by-patient basis. In general, a CBZ:ESL dose ratio of 1:1.3 should be employed to calculate the ESL target dose, and patients should be transitioned over a minimum period of 1–2 weeks. Special considerations include adjustment of titration schedule and target dose in elderly patients and those with hepatic or renal impairment and potential adjustment of comedications metabolized by CYP enzymes. In summary, due to structural distinctions between ESL, OXC, and CBZ, which affect mechanism of action and tolerability, there are clinical situations in which it may be appropriate to consider transitioning patients from OXC or CBZ to ESL. Changing patients over from OXC to ESL is generally more straightforward than transitioning patients from CBZ to ESL, which requires careful consideration. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.